Natural dipeptidyl peptidase-IV inhibitor mangiferin mitigates diabetes- and metabolic syndrome-induced changes in experimental rats
Rajesh Kumar Suman,1 Ipseeta Ray Mohanty,1 Ujwala Maheshwari,2 Manjusha K Borde,1 YA Deshmukh1 1Department of Pharmacology, 2Department of Pathology, MGM Medical College, Kamothe, Navi Mumbai, India Background: Mangiferin (MNG) is known to possess antidiabetic and antioxidant activity. However, ther...
Guardado en:
Autores principales: | Suman RK, Mohanty IR, Maheshwari U, Borde MK, Deshmukh YA |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f155ada8cef845c083ab819c9ee54af3 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Mangiferin Mitigates Lipopolysaccharide-Induced Lung Injury by Inhibiting NLRP3 Inflammasome Activation
por: Li N, et al.
Publicado: (2021) -
The role of dipeptidyl peptidase 4 inhibitors in fat metabolism in patients with type 2 diabetes and obesity
por: Aleksander Sergeevich Ametov, et al.
Publicado: (2015) -
Mangiferin: Analgesic properties in neuropathic pain, molecular docking and meta-analysis
por: Bo-tao Chang, et al.
Publicado: (2022) -
Mangiferin Inhibits Apoptosis and Autophagy Induced by Staphylococcus aureus in RAW264.7 Cells
por: Xu J, et al.
Publicado: (2020) -
Peripheral Neuropathy Presents Similar Symptoms and Pathological Changes in Both High-Fat Diet and Pharmacologically Induced Pre- and Diabetic Mouse Models
por: Julia Jaroslawska, et al.
Publicado: (2021)